Coronary StenosisIRISBioFreedomNCT03190057
IRIS-BioFreedom Cohort in the IRIS-DES Registry
An observational study of Coronary Stenosis, run by Seung-Jung Park at 8 sites in South Korea.
Trial summary
The objective of this study is to evaluate effectiveness and safety of BIOFREEDOM™ FAMILY stent in the "real world" daily practice as compared with other drug-eluting stents. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Coronary Stenosis
- What is being tested?
- BIOFREEDOM™ FAMILY stent
- Type of treatment
- Medical device
- How many people
- 218 participants
- Where
- 8 sitesSouth Korea
- Study dates
- 20 May 2019to 29 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with BIOFREEDOM™ FAMILY stent
Who may be able to join
- Age 19 and more
- Patient with BIOFREEDOM™ FAMILY stent
- Written consent
Who cannot join
- Intervention with BIOFREEDOM™ FAMILY stent and other drug eluting stent at the same time
- Life-expectancy less than 1 year
- Cardiac shock
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
South Korea8 sites
Hallym University Sacred Heart Hospital
Anyang
Soonchunhyang University Hospital, Cheonan
Cheonan
The Catholic University of Korea, Daejeon ST. Mary's Hospital
Daejeon
Chonnam National University Hospital
Gwangju
Gachon University Gil Hospital
Incheon
Inje University Pusan Paik Hospital
Pusan
Asan Medical Center
Seoul
Eulji General Hospital
Seoul
About this study
Official title: Evaluation of Effectiveness and Safety of BIOFREEDOM™ FAMILY Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
The objective of this study is to evaluate effectiveness and safety of BIOFREEDOM™ FAMILY stent in the "real world" daily practice as compared with other drug-eluting stents.
Read the detailed description
BIOFREEDOM™ FAMILY stent means that Biofreedom stent, Biofreedom Ultra and the other stents with names starting with Biofreedom.
- Conditions
- Coronary Stenosis
- Being tested
- BIOFREEDOM™ FAMILY stent
- Keywords
- BioFreedom, Drug Eluting Stent, Coronary Artery Disease
- Medical subject headings
- Coronary Stenosis, Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BIOFREEDOM™ FAMILY stentDevice
Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
| Study group | Role | What they receive |
|---|---|---|
| Consecutive percutaneous coronary intervention | Not described Receives: Device: BIOFREEDOM™ FAMILY stent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR)
Measured: 1 year
Secondary outcomes (10)
All cause death
Measured: 5 year
Cardiac death
Measured: 5 year
Myocardial Infarction
Measured: 5 year
Composite event rate of death or myocardial infarction (MI)
Measured: 5 year
Composite event rate of cardiac death or myocardial infarction (MI)
Measured: 5 year
Target- Vessel Revascularization
Measured: 5 year
Target- Lesion Revascularization
Measured: 5 year
Stent thrombosis
Measured: 5 year
Stroke
Measured: 5 year
Procedural Success rate
defined as achievement of a final diameter stenosis of <30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.
Measured: 5 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2017
- Study start20 May 2019
- Primary completion29 Sep 2025
- Study completion29 Sep 2025
Why it stopped: Funding issue
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 218 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seung-Jung Park
- Sponsor type
- University, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- Responsible party
- Sponsor-investigator, Seung-Jung Park, Asan Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03190057
- Sponsor's protocol ID
- AMCCV2017-04
- Acronym
- IRISBioFreedom
- Status last verified
- Sep 2025
- First submitted
- 13 Jun 2017
- Last updated
- 30 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Effectiveness and Safety of BIOFREEDOM™ FAMILY Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
- ClinicalTrials.gov ID
- NCT03190057
- Acronym / sponsor ID
- IRISBioFreedom / AMCCV2017-04
- Conditions
- Coronary Stenosis
- Keywords
- BioFreedom, Drug Eluting Stent, Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Funding issue
- Enrolment
- 218 participants (actual)
- Lead sponsor
- Seung-Jung ParkUniversity, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- Study start
- 20 May 2019 (actual)
- Primary completion
- 29 Sep 2025 (actual)
- Study completion
- 29 Sep 2025 (actual)
- First posted
- 16 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate effectiveness and safety of BIOFREEDOM™ FAMILY stent in the "real world" daily practice as compared with other drug-eluting stents.
Detailed description
BIOFREEDOM™ FAMILY stent means that Biofreedom stent, Biofreedom Ultra and the other stents with names starting with Biofreedom.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Consecutive percutaneous coronary intervention | – | Device: BIOFREEDOM™ FAMILY stent |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with BIOFREEDOM™ FAMILY stent
Key inclusion criteria (3 listed)
- Age 19 and more
- Patient with BIOFREEDOM™ FAMILY stent
- Written consent
Key exclusion criteria (3 listed)
- Intervention with BIOFREEDOM™ FAMILY stent and other drug eluting stent at the same time
- Life-expectancy less than 1 year
- Cardiac shock
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BIOFREEDOM™ FAMILY stentPercutaneous coronary intervention with BIOFREEDOM™ FAMILY stent | Device | Consecutive percutaneous coronary intervention |
Primary outcome
Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR)
Time frame: 1 year
10 secondary outcomes
All cause death
Time frame: 5 year
Cardiac death
Time frame: 5 year
Myocardial Infarction
Time frame: 5 year
Composite event rate of death or myocardial infarction (MI)
Time frame: 5 year
Composite event rate of cardiac death or myocardial infarction (MI)
Time frame: 5 year
Target- Vessel Revascularization
Time frame: 5 year
Target- Lesion Revascularization
Time frame: 5 year
Stent thrombosis
Time frame: 5 year
Stroke
Time frame: 5 year
Procedural Success rate
Time frame: 5 day
Results and safety
The study was stopped early (reason given: Funding issue). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Stenosis
RecruitingObservational study
Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT Registry™): Registry Purpose and Research Objective
Aortic Valve Stenosis
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Active, not recruiting
Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
Aortic Stenosis
RecruitingObservational study
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
Hypertrophic Cardiomyopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Stenosis, run by Seung-Jung Park at 8 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 30 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Funding issue). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR) (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2025.